Publications

Rodriguez-Otero P, Morillo D, D'Souza A, Reece D, van de Donk N, Chari A, Dholaria B, Kortüm KM, Mateos MV, Mckay JT, Rosiñol L, Sureda A, Wäsch R, Bhutani M, Weisel KC, Bahlis NJ, Vishwamitra D, Skerget S, Bakshi KK, Guo Y, Sun W, Goldberg JD, Stephenson T, Prior TJ, Vandenberk L, Lee S, Smit MD, Verona RI, Oriol A, Krishnan A. Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study. Blood advances. 2026. PMID: 42685673

Lee EY, Tang W, Price JC, Kelley RK, Gordan JD, Lai JC, Fong L, Mehta N, Li M. Impact of hepatitis C viremia on overall survival and hepatic decompensation among patients with unresectable HCC receiving immunotherapy. Clinical and translational gastroenterology. 2026. PMID: 42684843

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies. Cancer. 2026. PMID: 42675812

Chari A, Voorhees PM, Thertulien R. Practical approach to second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: Q&A. Clinical advances in hematology & oncology : H&O. 2026. PMID: 42748350

Chari A, Voorhees PM, Thertulien R. Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association. Clinical advances in hematology & oncology : H&O. 2026. PMID: 42748346

Chari A. Relapsed/refractory multiple myeloma: disease overview and treatment landscape. Clinical advances in hematology & oncology : H&O. 2026. PMID: 42748347

Chari A, Touzeau C, Berdeja JG, Oriol A, van de Donk NW, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Masterton T, Tolbert J, Renaud T, Kane C, Heuck C, Moreau P. Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study. Future oncology (London, England). 2026. PMID: 42669079

Chiang AY, Vijayaraghavan M. Intersectional Disparities in Adult Cigarette Smoking, E-Cigarette Use, and Cannabis Use Among Sexual and Gender and Racial and Ethnic Minorities in California. American journal of public health. 2026. PMID: 42659581

Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, Basu S, Hulin C, Zweegman S, Weisel K, Perrot A, Jacquet C, Raje N, Manier S, Chari A, Hansson M, Mohty M, Delforge M, Plesner T, Cook G, Leleu X, Quach H, Venner CP, Tiab M, Macro M, Frenzel L, Wang G, Pei H, Bolyard K, Carson R, Borgsten F, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia. 2026. PMID: 42637879

Yang X, Dumke H, Kambhampati Thiruvengadam S, Argao C, Schroers-Martin JG, Lanka S, Sawalha Y, Alharthy H, Ahmed S, Okcu I, Nowakowski GS, Doukas PG, Karmali R, Shanmugasundaram K, Colton M, Spinner MA, Marron Rodriguez S, DuVall AS, Lakin BG, D'Angelo CR, Pizzuti VJ, Kamdar M, Adewale O, Rhodes JM, Tiger YKR, Baron K, Bock AM, Geer MJ, Karimi YH. Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma. Blood advances. 2026. PMID: 42623675

Kretschmer LS, Mitchell DC, Liu J, Leak L, Turnham RE, Wang L, Wang Z, He C, Ding L, Adler M, Kellett T, Keith A, Hwang YC, Chan GKL, Gottschalk RLG, Li W, Chan LM, Ramamoorthi R, Lively S, Drakas RA, Ramani V, Qing T, Verba KA, Bivona T, Ostrem JML, Beresis RT, Gordan JD. Small-molecule activation of the tumor suppressor kinase LKB1 via the pseudokinase STRAD. Cell chemical biology. 2026. PMID: 42612636

Kelley RK, Bracci P, Gordan JD, Behr SC, Quandt Z, Atreya CE, Kidder WA, Ko AH, Lim HC, Van Loon K, Adeniji N, Venook AP, Fong L, Keenan BP. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42599167

Gould P, Coskey D, Ma X, Wang S, Godbole S, Bond D, Ip A, Ananth S, Varma S, Ayers E, Faden R, Gillespie C, William B, Jacobs R, Hu B, Lattin J, Russler-Germain D, Stanchina M, Rose A, Randall M, Spinner M, Srikakulapu V, Geethakumari PR, Skarbnik A, Chitty DW, Tsang M, Duarte C, Major A, Bock AM, Baron K, Hess B, Tolu S, Pro B, Vaidya S, Amengual JE, Reshef R, Cherng HJ. Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes. Haematologica. 2026. PMID: 42610418

Nagpal S, Carlson-Clarke B, Rout SS, Trinh TTH, Roy-O'Reilly M, Tedjakusuma SN, Taiwo R, Harary PM, Granucci M, Chernikova SB, Bertrand S, Therkelsen KE, Han SS, Gu B, Bharani KL, Newman JM, Barisano G, Umeh-Garcia MC, Herrick D, Vogel H, Arora M, Samos CH, Soltys SG, Pollom EL, Rahimy E, Iv M, Melisko ME, Hayden Gephart M. Phase 2 test of QBS72S for breast cancer leptomeningeal disease. Neuro-oncology. 2026. PMID: 42565554

Rasche L, Schinke C, Touzeau C, Minnema MC, van de Donk N, Rodriguez-Otero P, Mateos MV, Ye JC, Tomlinson C, Vishwamitra D, Singh I, Qin X, Campagna M, Masterson T, Vreys V, Lau BW, Tolbert J, Renaud T, Heuck C, Chari A. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. Blood. 2026. PMID: 42561120

Norouzi A, Johnson K, Avelar K, Civantos A, Ilan A, Durr ML, Patel Y, Paciorek A, Zhang L, Eltawil Y, Alqasieer Y, Kim K, Graham J, Ha P, Chan J, Yom SS, Ross L, Li S, Brodie S, Xu MJ. Post-Radiation Dental Care Access Among Head and Neck Cancer Survivors: A Safety Net Perspective. Laryngoscope investigative otolaryngology. 2026. PMID: 42568617

Rugo HS, Ryan JC. P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast. Targeted oncology. 2026. PMID: 42560565

Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, Brown-Swigart L, Hirst GL, Yau C, I-SPY2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, van 't Veer LJ, Rosenbluth JM. Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine. 2026. PMID: 42561946

Gu D, Chakravarty D, Cuby J, Hall S, Stitzer M, Kushel M, Xia F, Vijayaraghavan M. Contingency Management for Smoking Cessation Among Adults Experiencing Homelessness: A Pilot Randomized Clinical Trial. JAMA network open. 2026. PMID: 42579279

Rugo HS, Schmid P, Cortes J, Takano T, Fasching PA, Park YH, Bianchini G, Franco SX, Villarreal-Garza C, Tredan O, Yin Y, Barroso-Sousa R, Peng X, Malhotra U, Smith KL, Bardia A. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England). 2026. PMID: 42535874